NO20055305D0 - Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase - Google Patents

Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase

Info

Publication number
NO20055305D0
NO20055305D0 NO20055305A NO20055305A NO20055305D0 NO 20055305 D0 NO20055305 D0 NO 20055305D0 NO 20055305 A NO20055305 A NO 20055305A NO 20055305 A NO20055305 A NO 20055305A NO 20055305 D0 NO20055305 D0 NO 20055305D0
Authority
NO
Norway
Prior art keywords
glycogen phosphorylase
pyrrolopyridine
carboxylic acid
acid amide
inhibitors
Prior art date
Application number
NO20055305A
Other languages
English (en)
Other versions
NO332265B1 (no
NO20055305L (no
Inventor
Karen Lesley Schofield
Stuart Edward Bradley
Thomas Martin Krulle
Peter John Murray
Martin James Procter
Robert John Rowley
Colin Peter Sambrook Smith
Gerard Hugh Thomas
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of NO20055305D0 publication Critical patent/NO20055305D0/no
Publication of NO20055305L publication Critical patent/NO20055305L/no
Publication of NO332265B1 publication Critical patent/NO332265B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20055305A 2003-05-21 2005-11-10 Pyrrolopyridin-2-karboksylsyreamidinhibitorer, fremstilling av og mellomprodukter ved fremstilling av slike, preparater og kombinasjoner omfattende slike, slike forbindelser og preparater som medikament samt slike forbindelser for behandling av sykdom NO332265B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47237503P 2003-05-21 2003-05-21
US55125604P 2004-03-08 2004-03-08
PCT/US2004/016243 WO2004104001A2 (en) 2003-05-21 2004-05-20 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase

Publications (3)

Publication Number Publication Date
NO20055305D0 true NO20055305D0 (no) 2005-11-10
NO20055305L NO20055305L (no) 2005-12-15
NO332265B1 NO332265B1 (no) 2012-08-13

Family

ID=33479321

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055305A NO332265B1 (no) 2003-05-21 2005-11-10 Pyrrolopyridin-2-karboksylsyreamidinhibitorer, fremstilling av og mellomprodukter ved fremstilling av slike, preparater og kombinasjoner omfattende slike, slike forbindelser og preparater som medikament samt slike forbindelser for behandling av sykdom

Country Status (16)

Country Link
EP (1) EP1636224B1 (no)
JP (2) JP2006528702A (no)
KR (1) KR101120935B1 (no)
AT (1) ATE473974T1 (no)
AU (1) AU2004240946B8 (no)
BR (1) BRPI0410445B1 (no)
CA (1) CA2525502C (no)
DE (1) DE602004028122D1 (no)
EA (1) EA009215B1 (no)
IL (1) IL171851A (no)
MA (1) MA27809A1 (no)
MX (1) MXPA05012547A (no)
NO (1) NO332265B1 (no)
NZ (1) NZ543482A (no)
UA (1) UA84146C2 (no)
WO (1) WO2004104001A2 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
WO2005047251A1 (en) * 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists
US7884112B2 (en) 2004-03-08 2011-02-08 Stuart Edward Bradley Pyrrolopyridine-2-carboxylic acid hydrazides
EP1732566A4 (en) * 2004-04-05 2010-01-13 Takeda Pharmaceutical 6-azaindole COMPOUND
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
WO2006059164A2 (en) 2004-12-02 2006-06-08 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amides
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
PL1819704T3 (pl) 2004-12-02 2008-12-31 Prosidion Ltd Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej
CA2626190A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
CN101331131A (zh) * 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
EP2340243B1 (en) 2008-10-17 2014-10-08 Boehringer Ingelheim International GmbH Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2714662B1 (en) 2011-05-31 2017-10-11 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
ES2642883T3 (es) 2011-05-31 2017-11-20 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
WO2012166390A1 (en) * 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
BR112015003098A2 (pt) 2012-08-17 2017-08-22 Bayer Cropscience Ag Azaindolecarboxamidas e azaindoletiocarboxamidas como inseticidas e acaricidas.
CN103626825B (zh) * 2013-09-30 2015-10-07 承德医学院 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent
EP4066896A4 (en) * 2019-11-27 2024-03-27 Riken G9A INHIBITOR
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
CN117836270A (zh) * 2021-03-10 2024-04-05 文森雷生物科学股份有限公司 Usp30抑制剂及其用途
WO2023165168A1 (zh) * 2022-10-27 2023-09-07 常州大学 吡唑类衍生物作为β2肾上腺素受体别构调节剂,拮抗剂和激动剂的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619915A (en) * 1984-10-19 1986-10-28 Pfizer Inc. Peptide-substituted heterocyclic immunostimulants
IL88619A0 (en) * 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
EP0712844A4 (en) * 1994-06-06 1996-11-06 Green Cross Corp NOVEL CARBOXYLIC ACID COMPOUND WITH FUSED CORE OR SALT THEREOF, AND ITS USE IN MEDICINE
US6107329A (en) * 1995-06-06 2000-08-22 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
KR100241643B1 (ko) * 1995-06-06 2000-03-02 디. 제이. 우드 당뇨병치료제인 치환된 N-(인돌-2-카르보닐)-β-알라님아미드 및 그의 유도체
DE69522718T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
EP1088824B1 (en) * 1999-09-30 2004-01-07 Pfizer Products Inc. Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
MXPA05004715A (es) * 2002-10-30 2005-08-03 Merck Frosst Canada Inc Derivados de piridopirrolizina y piridoindolizina.

Also Published As

Publication number Publication date
EP1636224B1 (en) 2010-07-14
AU2004240946B8 (en) 2012-01-12
EP1636224A2 (en) 2006-03-22
KR20060069792A (ko) 2006-06-22
AU2004240946B2 (en) 2011-09-08
JP2006528702A (ja) 2006-12-21
EA200501645A1 (ru) 2006-06-30
EA009215B1 (ru) 2007-12-28
WO2004104001A3 (en) 2005-03-03
JP5669691B2 (ja) 2015-02-12
IL171851A (en) 2011-08-31
AU2004240946A1 (en) 2004-12-02
WO2004104001A2 (en) 2004-12-02
JP2011252005A (ja) 2011-12-15
CA2525502C (en) 2012-12-18
CA2525502A1 (en) 2004-12-02
ATE473974T1 (de) 2010-07-15
DE602004028122D1 (de) 2010-08-26
UA84146C2 (ru) 2008-09-25
NO332265B1 (no) 2012-08-13
NO20055305L (no) 2005-12-15
KR101120935B1 (ko) 2012-03-05
NZ543482A (en) 2009-02-28
BRPI0410445B1 (pt) 2017-11-28
BRPI0410445A (pt) 2006-05-30
MXPA05012547A (es) 2006-05-25
MA27809A1 (fr) 2006-03-01

Similar Documents

Publication Publication Date Title
NO20055305D0 (no) Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase
ATE424821T1 (de) Pyrrolopyridin-2-karbonsäureamide
ATE483708T1 (de) Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
JO2282B1 (en) Oxazole derivatives
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
NO20051527D0 (no) 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
ATE368647T1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
ATE384058T1 (de) Thiazolderivate
DK1088824T3 (da) Bicykliske pyrrolylamider som glycogen phosphorylase inhibitorer
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
GB0413087D0 (en) Therapeutic compounds
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20082496L (no) Pyrazinderivater
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
WO2005085194A3 (en) Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors
SE9902267D0 (sv) New compounds
BR0212899A (pt) Compostos orgânicos
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees